 |
|
Mass. General study finds potential ovarian cancer stem cells
July 24, 2006Cells may underlie tumor recurrence and resistance, suggest new treatment approaches
Massachusetts General Hospital (MGH) researchers have identified potential ovarian cancer stem cells, which may be behind the difficulty of treating these tumors with standard chemotherapy. Understanding more about the stem-like characteristics of these cells could lead to new approaches to treating ovarian cancer, which kills more than 16,000 U.S. women annually and is their fifth most common cause of cancer death. The report will appear in the July 25 Proceeding of the National Academy of Sciences (PNAS) and has received early online release.
"We feel these stem-like cancer cells may be resistant to traditional chemotherapy and could be responsible for the ultimately fatal drug-resistant recurrence that is characteristic of ovarian cancer," says Paul Szotek, MD, of the MGH Pediatric Surgical Research Laboratories, first author of the PNAS report. "We believe this likely is the first time stem-like cells have been found in models of ovarian cancer and in cells associated with human ovarian cancer."
Several recent studies have identified tiny populations of tumor cells that appear to act like stem cells, driving the tumor's ability to grow and spread. If some of these specialized cells escaped destruction by chemotherapy or radiation, the tumor would be able to recur quickly, often in a form resistant to chemotherapy. Similar cancer stem cells have been previously identified in leukemia and breast cancer and in cell lines of central nervous system and gastrointestinal tumors.
Standard treatment for ovarian cancer - surgical removal of all involved tissues followed by chemotherapy - usually appears successful, but treatment-resistant tumors recur in the vast majority of patients, leading to a five-year survival rate of less than 30 percent. Those factors and other observations suggested that cancer stem cells may also be found with ovarian tumors, leading to the current study.
The MGH researchers first examined two mouse ovarian cancer cell lines and identified cells with characteristics of the cancer stem cells found with other tumors. They then observed a small percentage of stem-like cells in human ovarian cancer lines and in cells taken from ascites fluid that had accumulated within the abdomen of several ovarian cancer patients. When mouse ovarian tumor stem-like cells were injected under the skin of mice, they led to the formation of new tumors much faster than did injections of regular tumor cells.
Although the potential ovarian cancer stem cells were less responsive than regular tumor cells to in vitro treatment with the chemotherapy drug doxorubicin, the stem-like cells remained sensitive to repeated treatment with Mullerian Inhibiting Substance (MIS). This protein, important in the normal development of sexual organs, has been studied for its potential to treat several reproductive tumors by Patricia Donahoe, MD, director of the MGH Pediatric Surgical Research Laboratories and senior author of the PNAS study, and David MacLaughlin, PhD, associate director of the labs and a study co-author.
"We feel that non-traditional, possibly innovative approaches will be required to eradicate these stem-like cancer cells and ultimately cure ovarian cancer. With its potential to maintain the ability to inhibit the proliferation of these cells, MIS may play a role in these new therapeutic approaches," Donahoe says. "We intend to keep searching for stem-like cells in patient tumor samples and to study their responsiveness to both chemotherapeutic agents and to novel agents specifically targeted to stem cell as individualized therapy of the future." Donahoe is the Marshall K. Bartlett Professor of Surgery at Harvard Medical School.
Massachusetts General Hospital
Several recent studies have identified tiny populations of tumor cells that appear to act like stem cells, driving the tumor's ability to grow and spread. If some of these specialized cells escaped destruction by chemotherapy or radiation, the tumor would be able to recur quickly, often in a form resistant to chemotherapy. Similar cancer stem cells have been previously identified in leukemia and breast cancer and in cell lines of central nervous system and gastrointestinal tumors.
Standard treatment for ovarian cancer - surgical removal of all involved tissues followed by chemotherapy - usually appears successful, but treatment-resistant tumors recur in the vast majority of patients, leading to a five-year survival rate of less than 30 percent. Those factors and other observations suggested that cancer stem cells may also be found with ovarian tumors, leading to the current study.
The MGH researchers first examined two mouse ovarian cancer cell lines and identified cells with characteristics of the cancer stem cells found with other tumors. They then observed a small percentage of stem-like cells in human ovarian cancer lines and in cells taken from ascites fluid that had accumulated within the abdomen of several ovarian cancer patients. When mouse ovarian tumor stem-like cells were injected under the skin of mice, they led to the formation of new tumors much faster than did injections of regular tumor cells.
Although the potential ovarian cancer stem cells were less responsive than regular tumor cells to in vitro treatment with the chemotherapy drug doxorubicin, the stem-like cells remained sensitive to repeated treatment with Mullerian Inhibiting Substance (MIS). This protein, important in the normal development of sexual organs, has been studied for its potential to treat several reproductive tumors by Patricia Donahoe, MD, director of the MGH Pediatric Surgical Research Laboratories and senior author of the PNAS study, and David MacLaughlin, PhD, associate director of the labs and a study co-author.
"We feel that non-traditional, possibly innovative approaches will be required to eradicate these stem-like cancer cells and ultimately cure ovarian cancer. With its potential to maintain the ability to inhibit the proliferation of these cells, MIS may play a role in these new therapeutic approaches," Donahoe says. "We intend to keep searching for stem-like cells in patient tumor samples and to study their responsiveness to both chemotherapeutic agents and to novel agents specifically targeted to stem cell as individualized therapy of the future." Donahoe is the Marshall K. Bartlett Professor of Surgery at Harvard Medical School.
Massachusetts General Hospital
Ovarian Cancer Current Events and Ovarian Cancer News RSSDisease diagnosis in just 15 minutes
Testing for diseases such as cancer and multiple sclerosis could soon be as simple as using a pregnancy testing kit.
Bio-imaging mass spectrometry techniques reveal molecular details about complex systems
Understanding biology at the systems level is difficult, especially when studying complex specimens like tissue slices or communities of organisms in a biofilm. Scientists must be able to identify, quantify and locate the molecules present in the samples.
Jefferson scientists deliver toxic genes to effectively kill pancreatic cancer cells
A research team, led by investigators at the Department of Surgery at Jefferson Medical College of Thomas Jefferson University and the Kimmel Cancer Center at Jefferson, has achieved a substantial "kill" of pancreatic cancer cells by using nanoparticles to successfully deliver a deadly diphtheria toxin gene.
Promising new treatment option for women with recurrent ovarian cancer
Combining the new drug trabectedin with pegylated liposomal doxorubicin provides clinical benefit to women with relapsed ovarian cancer, according to new results presented at the 33rd Congress of the European Society for Medical Oncology (ESMO) in Stockholm.
Risk of breast cancer mutations underestimated for Asian women, Stanford study shows
Oncologist Allison Kurian, MD, and her colleagues at the Stanford University School of Medicine were perplexed. Computer models designed to identify women who might have dangerous genetic mutations that increase their risk of breast and ovarian cancer worked well for white women. But they seemed to be less reliable for another ethnic group.
Cryopreservation techniques bring hopes for women cancer victims and endangered species
Emerging cryopreservation techniques are increasing hope of restoring fertility for women after diseases such as ovarian cancer that lead to destruction of reproductive tissue.
Study challenges routine use of MRI scans to evaluate breast cancer
A new study suggests women with newly-diagnosed breast cancer who receive an MRI after their diagnosis face delays in starting treatment and are more likely to receive a mastectomy.
Variation of normal protein could be key to resistance to common cancer drug
Researchers at the Moores Cancer Center at the University of California, San Diego (UC SD) in La Jolla have found evidence explaining why a common chemotherapy drug, cisplatin, may not always work for every cancer patient. They have shown that when a variant version of a key protein that normally causes cell death is active, patients may be resistant to the cancer-killing drug.
New method to overcome multiple drug resistant diseases developed by Stanford researchers
Many drugs once considered Charles Atlases of the pharmaceutical realm have been reduced to the therapeutic equivalent of 97-pound weaklings as the diseases they once dispatched with ease have developed resistance to them.
How chemo kills tumours: research to reduce side effects
Dr Stephen Taylor and Karen Gascoigne at the University's Faculty of Life Sciences have taken a new systematic approach to studying anti-mitotic drugs, which are used extensively for breast or ovarian cancer in the UK.
More Ovarian Cancer Current Events and Ovarian Cancer News Articles
 | A Guide to Survivorship for Women with Ovarian Cancer (A Johns Hopkins Press Health Book) by F. J. Montz, Robert E. Bristow This comprehensive guide to ovarian cancer offers a wealth of information to ease the physical, emotional, and psychic suffering of women with the disease. The authors -- two Johns Hopkins gynecologic oncologists and a gynecologic-oncology clinical nurse -- put particular emphasis on the concept of "survivorship," or living life well in the face of daunting uncertainties. They stress the... |
 | Ovarian Cancer Journeys: Survivors Share Their Stories To Help Others by Ayala Miron "All of the research has reinforced that ovarian cancer is not a silent disease as was once thought and as is shown quite eloquently in this collection of stories.... The value of this collection of stories is that it helps raise awareness about symptoms, need for patient persistence, and the importance of being treated by a gynecologic oncologist." Barbara A. Goff, MD Professor and... |
 | Beating Ovarian Cancer: How To Overcome The Odds And Reclaim Your Life by Chris Bledy A diagnosis of Ovarian Cancer does not have to be a death sentence. Recent advances in medicine have made this once incurable disease treatable and manageable. You can beat advanced and even recurring, ovarian cancer. Simple but significant lifestyle changes can produce big results when it comes to... |
 | Ovarian Cancer (Patient-Centered Guides) by Kristine Conner, Lauren Langford This unique guide for ovarian cancer gives women crucial medical information to improve the chance for lengthy remission and cure, as well as emotional support for the journey. Although many ovarian cancers are discovered after they have spread, having information about surgery and best practices can be life-saving. For example, choosing a surgeon from the new specialty of gynecologic oncology... |
 | Gilda's Disease: Sharing Personal Experiences and a Medical Perspective on Ovarian Cancer by Steven Piver The first book on ovarian cancer for the general reader, this is a comprehensive, compassionate look at a disease millions of people first became aware of with the tragic death of comedienne Gilda Radner in 1989. Dr. Piver, a leading cancer surgeon, discusses the causes of ovarian cancer, preventative measures, classic signs and symptoms, diagnostic tests and genetic screening, the different... |
 | 100 Questions & Answers About Ovarian Cancer, Second Edition by Don S. Dizon Whether you're a newly diagnosed ovarian cancer patient, a survivor, or a friend or relative of either, this completely updated second edition gives you authoritative, practical answers to your questions about treatment options, post-treatment quality of life, sources of support, and much more. Written by a gynecologic oncologist and a gynecologic surgeon, with actual patient commentary, ... |
 | 100 Q&A About Ovarian Cancer by Don S. Dizon Covers a wide range of topics, including ovarian cancer; risk factors, diagnosis, treatment and side effects; and strategies for coping with emotional and healthcare... |
 | A Feather in My Wig: Ovarian Cancer Cured, Seventeen Years and Going Strong! by Barbara R. Van Billiard With sensitivity and with humor, Barbara Van Billiard sets down the facts of her struggle and outlines the steps she took to deal with surgeries and chemotherapy. Her use of, and explanation, of various mind-body techniques, such as imagery and meditation, are a thought provoking approach that any cancer patient could use to help with life threatening... |
 | Ovarian Cancer: State of the Art and Future Directions in Translational Research (Advances in Experimental Medicine and Biology) (Advances in Experimental Medicine and Biology) Aegean Conferences is an independent, nonprofit, educational organization directed and managed by the scientific community. The board is made up of nine researchers/scientists in various disciplines from Harvard, Brown, University of Pennsylvania, UCSD, Princeton, Biovista and the Foundation for Biomedical Research Academy of Athens. The board both invites and approves unsolicited proposals for... |
 | Cancer and Death: A Love Story in Two Voices (Health Communication) by Leah Vande Berg, Nick Trujillo In this book, Leah and Nick tell the story of their lives together and about how their love for each other sustained them during Leah's 14-month ordeal with Stage IV ovarian cancer. This book is one of the most honest accounts ever written about cancer, death, grief and... |
| © 2008 BrightSurf.com |